Ò¼ºÅÓéÀÖAPP

Ò¼ºÅÓéÀÖAPP | ENGLISH
ÉúÎï¿Æ¼¼Óë´ó¿µ½¡Ñ§ÔºÅíʿӸ±½ÌÊÚ¿ÎÌâ×éÔÚ¹ú¼Ê¶¥¼¶ÆÚ¿¯¡¶ACS Catalysis¡·½ÒÏþÑо¿ÂÛÎÄ
ä¯ÀÀ£º£º£º  Ðû²¼Ê±¼ä£º£º£º2023Äê04ÔÂ19ÈÕ

¿ËÈÕ£¬ÎÒУÅíʿӸ±½ÌÊÚ¿ÎÌâ×éÔÚ¹ú¼Ê»¯Ñ§ÖøÃû¿¯Îï¡¶ACS Catalysis¡·ÉϽÒÏþÁËÌâΪ¡°Asymmetric (5 + 3) Annulation of Donor?Acceptor Cyclopropanes with Imidazolidines: Access to Saturated 1,4-Diazocanes¡±µÄÑо¿ÂÛÎÄ(ACS Catal. 2023 ,13, 5752¨C5758)¡£¡£¡£¡£

7C7FC3CF45AAFAE2FD3BBAAE387_054DE486_826B

±¥ºÍ1,4-¶þµªÔÓ»·£¬°üÀ¨ßßມ¢¡¢1,4-¶þµªÔÓ¸ýÍéºÍ1,4-¶þµªÔÓÐÁÍ飬×÷ΪҪº¦½á¹¹ÆÕ±é±£´æÓÚÒ©ÎïºÍ×ÔÈ»²úÆ·ÖУ¬ÀýÈçIndinavir¡¢¡¢Aripiprazole¡¢¡¢Gatifloxacin¡¢¡¢Suvorexant¡¢¡¢FasudilºÍBenzolactam-V8¡£¡£¡£¡£ÓëÁùÔªßßàººÍÆßÔª1,4-¶þµªÔÓ¸ýÍéÏà±È£¬°ËÔª»·1,4-¶þµªÔÓÐÁÍéµÄºÏ³ÉÃæÁÙÖØ´óÌôÕ½¡£¡£¡£¡£ÏÖÔÚ¸ßЧºÏ³É1,4-¶þµªÔÓÐÁÍéµÄ·´Ó³±¨µÀµÄºÜÉÙ£¬ÇÒ¶¼±£´æÒ»¶¨µÄ¾ÖÏÞÐÔ£º£º£º·´Ó³Ìõ¼þ¿Á¿Ì£¬ÖÊÁϺϳÉÄÑÌ⣬²úÂÊÆÕ±é½ÏµÍ£¬¹ÙÄÜÍżæÈÝÐԽϲîµÈ¡£¡£¡£¡£Òò´Ë£¬¿ª·¢Ò»ÖÖ´Ó¼òÆÓÒ×µÃµÄÆðʼÖÊÁϸßЧºÏ³É1,4-¶þµªÔÓÐÁÍéµÄÒªÁì¾ßÓÐÖ÷ÒªÒâÒå¡£¡£¡£¡£

¸ÃÊÂÇéÆ¾Ö¤Ç°ÆÚÑо¿Ð§¹û(Org. Lett. 2022, 24, 6443?6448£»£»ACS Catal. 2022, 12, 14647?14653)£¬¿ªÕ¹ÁËÒ»ÖÖÍ­´ß»¯µÄDACÓëßäßòßøµÄ(5 + 3)»·¼Ó³É·´Ó³£¬ÔÚÎÂ˳Ìõ¼þÏÂÒÔÖеÈÖÁÓÅÒìµÄ²úÂÊ»ñµÃÁËһϵÁб¥ºÍµÄ1,4-¶þµªÔÓÐÁÍ黯ºÏÎï¡£¡£¡£¡£½øÒ»²½Í¨¹ýÊÖÐÔ×ªÒÆ(Chirality Transfer)ºÍ¶¯Ì¬¶¯Á¦Ñ§²î³Ø³Æ×ª»¯(Dynamic Kinetic Asymmetric Transformation)Á½ÖÖÕ½ÂÔ£¬Ê×´ÎʵÏÖÁË1,4-¶þµªÔÓÐÁÍéµÄ²î³Ø³ÆºÏ³É¡£¡£¡£¡£

Ò¼ºÅÓéÀÖAPP2021¼¶Ñо¿ÉúÑîÁÁÁÁΪ¸ÃÂÛÎĵĵÚÒ»×÷Õߣ¬Ò¼ºÅÓéÀÖAPPÅíʿӸ±½ÌÊÚΪ¸ÃÂÛÎÄͨѶ×÷Õß¡£¡£¡£¡£¸ÃÊÂÇéÒÀÍÐÒ¼ºÅÓéÀÖAPPÉúÎï¿Æ¼¼Óë´ó¿µ½¡Ñ§Ôº×ÔÈ»²úÆ·ºÏ³É¼°ÒªÁìѧÍŶÓ£¬»ñµÃÁ˹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ðµÈ¾­·Ñ×ÊÖú¡£¡£¡£¡£

¡¶ACS Catalysis¡·ÊÇÃÀ¹ú»¯Ñ§»á£¨ACS£©Æì½¢¿¯Î×îÐÂÓ°ÏìÒò×ÓΪ13.7£¬Ö÷Òª¿¯µÇ´ß»¯»¯Ñ§ÁìÓò¸ßˮƽµÄÑо¿Ð§¹û£¬ÊôÓÚ»¯Ñ§Ñ§¿ÆTopÆÚ¿¯ÓëÖпÆÔº1ÇøÆÚ¿¯¡£¡£¡£¡££¨ÎÄ/ͼ ÉúÎï¿Æ¼¼Óë´ó¿µ½¡Ñ§Ôº£©

ÓÑÇéÁ´½Ó

Ò¼ºÅÓéÀÖAPPҩѧÓëʳÎ﹤³ÌѧԺ ?°æÈ¨ËùÓÐ  ÔÁICP±¸15096031ºÅ
ѧԺ°ì¹«ÊÒ£º£º£º£¨0750£©3299391
µØµã£º£º£º¹ã¶«½­ÃÅÊÐÅî½­Çø¶«³É´å22ºÅÀèÒ«»ªÂ¥  Óʱࣺ£º£º529020
¡¾ÍøÕ¾µØÍ¼¡¿